Sökning: "Pharmacokinetics Pharmacotherapy"
Visar resultat 1 - 5 av 14 avhandlingar innehållade orden Pharmacokinetics Pharmacotherapy.
1. Pharmacokinetics and Pharmacodynamics of Oxycodone and Morphine with Emphasis on Blood-Brain Barrier Transport
Sammanfattning : The pharmacokinetics and pharmacodynamics of oxycodone and morphine was investigated and related to the transport across the blood-brain barrier (BBB) in rats. The influence of a P-glycoprotein (P-gp) inhibitor on the plasma pharmacokinetics and pharmacodynamics of oxycodone was evaluated. LÄS MER
2. Pharmacodynamics of Enzyme Induction and its Consequences for Substrate Elimination
Sammanfattning : Enzyme induction is a process whereby a molecule enhances the expression of enzymes. If the affected enzymes are involved in the elimination of a drug, this may result in a drug interaction. Induction is therefore of major concern during drug development and in clinical practice. LÄS MER
3. Using Pharmacokinetic and Pharmacodynamic Principles to Evaluate Individualisation of Antibiotic Dosing – Emphasis on Cefuroxime
Sammanfattning : Cefuroxime is a renally eliminated antibiotic used against a variety of different bacterial infections. The pharmacokinetics (PK) for cefuroxime was studied in 97 hospitalized patients using population analysis. To be able to measure cefuroxime in human serum a new sensitive analytical method was developed using mass spectrometry detection. LÄS MER
4. Pharmacokinetic drug-drug interactions in the management of malaria, HIV and tuberculosis
Sammanfattning : Malaria, Human Immunodeficiency Virus (HIV) and tuberculosis (TB) are global health problems having their worst situation in sub-Saharan Africa. Consequently, concomitant use of antimalarial, antiretroviral and antitubercular drugs may be needed, resulting in a potential risk of drug-drug interactions. LÄS MER
5. Mechanism-Based Pharmacokinetic and Pharmacodynamic Modelling of Paclitaxel
Sammanfattning : Paclitaxel (Taxol®) is now widely used against breast, ovarian and non-small-cell lung cancer. Anticancer agents generally have narrow therapeutic indices, often with myelosuppression (mainly neutropenia) as dose-limiting side effect. LÄS MER